US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Swedish Orphan Biovitrum AB

30.56

-0.1900-0.62%

Volume:179.00

Turnover:5.47K

Market Cap:10.47B

PE:51.60

High:30.56

Open:30.56

Low:30.56

Close:30.75

52wk High:32.25

52wk Low:25.80

Shares:342.53M

Float Shares:218.79M

Volume Ratio:0.88

T/O Rate:0.00%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.5922

EPS(LYR):0.7424

ROE:11.57%

ROA:5.65%

PB:2.54

PE(LYR):41.16

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Apellis, Sobi present data from open-label period of Phase 3 VALIANT study

Swedish Orphan Biovitrum AB (BIOVF) Q1 2025 Earnings Call Highlights: Strong Haematology Growth ...

Sobi presents clinical data at WFH 2025 Comprehensive Care Summit

Invitation: Sobi's Q1 report

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BIOVF"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BIOVF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BIOVF\",,,,,undefined,":{"symbol":"BIOVF","market":"US","secType":"STK","nameCN":"Swedish Orphan Biovitrum AB","latestPrice":30.56,"timestamp":1756497600000,"preClose":30.75,"halted":0,"volume":179,"delay":15,"floatShares":218787594,"shares":342525575,"eps":0.592239,"marketStatus":"Market Closed","change":-0.19,"latestTime":"08-29 16:00:00 EDT Delay","open":30.56,"high":30.56,"low":30.56,"amount":5470.24,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":0.592239,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1756800000000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"PINK LIMITED","adjPreClose":30.75,"volumeRatio":0.8809049048883529},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BIOVF\",,,,,undefined,":{"symbol":"BIOVF","floatShares":218787594,"roa":"5.65%","roe":"11.57%","lyrEps":0.742401,"volumeRatio":0.8809049048883529,"shares":342525575,"dividePrice":0,"high":30.56,"amplitude":0,"preClose":30.75,"low":30.56,"week52Low":25.7957,"pbRate":"2.54","psRate":"3.67","week52High":32.25,"institutionHeld":0,"latestPrice":30.56,"eps":0.592239,"divideRate":0,"volume":179,"delay":15,"ttmEps":0.592239,"open":30.56,"prevYearClose":27.66,"prevWeekClose":30.75,"prevMonthClose":29.79,"prevQuarterClose":29.25,"fiveDayClose":30.75,"twentyDayClose":29.79,"sixtyDayClose":30.29},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BIOVF\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-04-25","symbol":"BIOVF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1714017600000,"reportTimeType":"","actualEps":null},{"date":"2022-10-27","symbol":"BIOVF","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1666857600000,"name":null,"time":"Pre-Market","dateTimestamp":1666843200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BIOVF\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BIOVF\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2308,"buy":0.4615,"hold":0.2308,"sell":0.0769,"strongSell":0,"meanLabel":"BUY","meanPercent":0.4615,"analysts":13,"updateTime":1754020800000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BIOVF\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2541863949","title":"Apellis, Sobi present data from open-label period of Phase 3 VALIANT study","url":"https://stock-news.laohu8.com/highlight/detail?id=2541863949","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541863949?lang=en_us&edition=fundamental","pubTime":"2025-06-06 21:25","pubTimestamp":1749216318,"startTime":"0","endTime":"0","summary":"Apellis Pharmaceuticals (APLS) and Sobi (BIOVF) presented new data from the open-label period of the Phase 3 VALIANT study, investigating EMPAVELI ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/apellis-sobi-present-data-from-open-label-period-of-phase-3-valiant-study-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/apellis-sobi-present-data-from-open-label-period-of-phase-3-valiant-study-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BIOVF","BK4505","BK4585","LU1093756168.USD","BK4588","LU1093756325.SGD","BK4139","APLS"],"gpt_icon":0},{"id":"2531370810","title":"Swedish Orphan Biovitrum AB (BIOVF) Q1 2025 Earnings Call Highlights: Strong Haematology Growth ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2531370810","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531370810?lang=en_us&edition=fundamental","pubTime":"2025-04-30 15:12","pubTimestamp":1745997170,"startTime":"0","endTime":"0","summary":"Revenue: SEK6.5 billion, 3% growth at constant currencies.Haemophilia A Sales: 29% growth at constant exchange rates.Immunology Decline: 21% decrease due to Synagis decline and Beyfortus seasonal shift.Adjusted Gross Margin: 77% in the quarter, up from 76% in Q1 2024.Operating Cash Flow: SEK2.3 billion, slightly higher than Q1 2024.Net Debt: SEK12.7 billion, net debt-to-EBITDA ratio of 1.3 times.Product Performance: Altuvoct 47% growth, Aspaveli 39%, Kineret 16%, Gamifant 31%.Vonjo Revenue: 6% decline due to stocking issues and gross-to-net adjustments.Geographic Performance: Europe 19% growth, North America 24%, International 38%.GuruFocus has detected 3 Warning Sign with BIOVF.For the complete transcript of the earnings call, please refer to the full earnings call transcript.Swedish Orphan Biovitrum AB  reported a strong first quarter with a 23% growth in their strategic portfolio, excluding seasonal RSV products and discontinued ReFacto manufacturing revenues.Swedish Orphan Biovitru","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/swedish-orphan-biovitrum-ab-biovf-071250024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AB","SNY","BIOVF","SWOBY"],"gpt_icon":0},{"id":"2529543052","title":"Sobi presents clinical data at WFH 2025 Comprehensive Care Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2529543052","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529543052?lang=en_us&edition=fundamental","pubTime":"2025-04-23 13:27","pubTimestamp":1745386020,"startTime":"0","endTime":"0","summary":"\"At WFH 2025 CCS, Sobi will present highlights from the XTEND phase 3 program and discuss the new treatment paradigm with FVIII levels in the non-haemophilia range. Sharing these clinical outcomes with the wider haemophilia community will help to ensure the latest treatment approaches are widely known and understood,\" said Lydia Abad-Franch, MD, MBA, Head of Research, Development, and Medical Affairs , and Chief Medical Officer at Sobi.Key data to be presented at WFH 2025 Comprehensive Care Summit, Dubai, UAEAltuvoct . A plain language summary of the associationbetween joint health and patient reportedquality of life outcomes using data from theefanesoctocog alfa Phase 3 clinical trial inadults and adolescents with severehaemophilia A                                   .Oral presentation: Oral FP-TH-02.5 Date: Thursday 24 April 2025 Time: 08:45 – 09:00  Location: Great Ballroom                       .Oral presentation: Oral FP-WE-01.5Date: Wednesday 23 April Time: 16:15 – 16:30 Location","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/sobi-presents-clinical-data-wfh-052700157.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sobi-presents-clinical-data-wfh-052700157.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SWOBY","BIOVF","WFH","SMMF","BK4211","BK4139"],"gpt_icon":0},{"id":"2527049505","title":"Invitation: Sobi's Q1 report","url":"https://stock-news.laohu8.com/highlight/detail?id=2527049505","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527049505?lang=en_us&edition=fundamental","pubTime":"2025-04-15 18:17","pubTimestamp":1744712220,"startTime":"0","endTime":"0","summary":"Investors, analysts, and the media are invited to a conference call on the same day at 15:30 CET, 14:30 GMT, and 09:30 EST. The call will include a presentation of the results and a Q&A session.The presentation can be followed live hereor afterwards on sobi.com. The slides will be made available on sobi.com before the conference call.To participate in the conference call, please use the following dial-in details:Sweden: +46 8 5051 0031United Kingdom: +44 207 107 06 13United States: +1 631 570 56 13For other countries, please find the detailshere.Sobi is a global biopharma company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share  is listed on Nasdaq Stockholm. More about Sobi at sobi.com and Linke","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/invitation-sobis-q1-report-101700133.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/invitation-sobis-q1-report-101700133.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SWOBY","BIOVF","BK4139"],"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":11,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/BIOVF\",params:#limit:6,delay:false,,,undefined,":[]}}